SPATA2 suppresses epithelial‐mesenchymal transition to inhibit metastasis and radiotherapy sensitivity in non–small cell lung cancer via impairing DVL1 /β‐catenin signaling
Thoracic Cancer · 2023
DOI: 10.1111/1759-7714.14828 ↗Kurz gefasst
Fachartikel in der Zeitschrift Thoracic Cancer, 2023. Verfasst von Hongbo Ji und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital, Key Laboratory of Cancer Prevention and Therapy, National…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Tianjin Municipal Science and Technology Commission.
Abstract (Originalsprache)
Metastasis is the major cause of cancer‐related death of cancer patients. Epithelial‐mesenchymal transition (EMT) is one critical process during the cascade of tumor metastasis. EMT is a developmental program exploited by cancer cells to transition from epithelial state to mesenchymal state and confers metastatic properties as well as treatment resistance. Finding factors to inhibit EMT will greatly improve the prognosis patients. Spermatogenesis associated 2 (SPATA2) was originally isolated from human testis and proved playing a role in spermatogenesis. To date, however, the role of SPATA2 in oncogenesis is unknown. In the current study, by mining the public database and validating in a cohort of collected non–small cell lung cancer (NSCLC) specimens, we uncovered that the expression of SPATA2 positively correlated with the prognosis of patients and was an independent prognosis marker in NSCLC. Functional studies proved that ectopic overexpression of SPATA2 inhibited EMT resulting in impaired motility and invasiveness properties in vitro and metastasis in vivo, and increased radiosensitivity in NSCLC. Mechanistic investigation showed that SPATA2 could suppress the β‐catenin signaling via attenuating DVL1 ubiquitination to achieve the functions. Taken together, the current study revealed an inhibitory role of SPATA2 on EMT and that SPATA2 could be a potential target for therapy of NSCLC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital, Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin's Clinical Research Cent…
- Department of Medical Oncology in Section One, Chifeng Municipal Hospital, Chifeng, China.
- Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
- Department of Public Laboratory, Tianjin Medical University Cancer Institute and Hospital, Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin's Clinical Research Cente…
ORCID-Profile: Zhiqiang Wu
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Tianjin Municipal Science and Technology Commission
Zitieren
APA
Ji, H., Zhang, L., Zou, M., Sun, Y., Dong, X., Mi, Z., Meng, M., Yuan, Z., & Wu, Z. (2023). SPATA2 suppresses epithelial‐mesenchymal transition to inhibit metastasis and radiotherapy sensitivity in non–small cell lung cancer via impairing DVL1 /β‐catenin signaling. Thoracic Cancer. https://doi.org/10.1111/1759-7714.14828
Vancouver
Ji H, Zhang L, Zou M, Sun Y, Dong X, Mi Z, et al. SPATA2 suppresses epithelial‐mesenchymal transition to inhibit metastasis and radiotherapy sensitivity in non–small cell lung cancer via impairing DVL1 /β‐catenin signaling. Thoracic Cancer. 2023. doi:10.1111/1759-7714.14828
BibTeX
@article{Ji2023,
author = {Ji, Hongbo and Zhang, Lu and Zou, Man and Sun, Yanchen and Dong, Xiaohan and Mi, Zeyun and Meng, Maobin and Yuan, Zhiyong and Wu, Zhiqiang},
title = {SPATA2 suppresses epithelial‐mesenchymal transition to inhibit metastasis and radiotherapy sensitivity in non–small cell lung cancer via impairing DVL1 /β‐catenin signaling},
journal = {Thoracic Cancer},
year = {2023},
doi = {10.1111/1759-7714.14828}
}
EUVIMED